Werewolf Therapeutics
About Werewolf Therapeutics
Werewolf Therapeutics, Inc. is an oncology biotherapeutics company unleashing the power of proinflammatory immune modulators to develop next-generation, transformative cancer therapeutics. The company is advancing a pipeline of treatments designed to focus the body’s immune response to selectively target cancer.
Under precise conditions, Werewolf’s technology allows it to zero in on tumors using validated mechanisms that are known cancer killers, while preventing unwanted side effects on non-target tissues – ultimately delivering a more clinically meaningful impact for patients.
Werewolf’s proprietary PREDATOR™ protein engineering platform combines a variety of approaches to actively silence the drug while in systemic circulation, optimize its pharmacokinetic profile, and rapidly and efficiently transform into the fully active state upon reaching the tumor microenvironment for maximum therapeutic potential.
Werewolf is creating a new era of tumor-selective, systemically delivered drugs with the potential to deliver more effective, less toxic treatments for people with cancer, with the goal of vastly improving their lives.
54 articles about Werewolf Therapeutics
-
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
11/22/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf, and Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will participate in a fireside chat at 8:20 AM ET on November 29 at the Evercore ISI HealthCONx Conference, taking place November 28-30, 2023, in Miami, Florida.
-
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
11/14/2023
Werewolf Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2023.
-
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
11/3/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced preliminary first-in-human clinical data from initial monotherapy dose-escalation cohorts in the Company’s lead clinical program, WTX-124x2101.
-
Werewolf Therapeutics to Present Clinical and Preclinical Data at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
10/31/2023
Werewolf Therapeutics, Inc. today announced that a poster describing interim first-in-human clinical results from initial monotherapy dose-escalation cohorts in the ongoing Phase 1/1b study of WTX-124 will be presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.
-
Werewolf Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
9/27/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced the publication of abstracts for upcoming poster presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting, taking place November 1-5, 2023 in San Diego, California.
-
Werewolf Therapeutics to Host KOL Event Highlighting IL-2 Landscape and Opportunity for WTX-124Virtual event to be held on Monday, September 18, 2023, at 10:00 am ET
9/11/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it will host a virtual R&D Event on Monday, September 18, 2023, at 10:00 am ET.
-
Werewolf Therapeutics to Participate in Upcoming September 2023 Investor Conferences
9/5/2023
Werewolf Therapeutics, Inc. announced that management will participate in the following upcoming investor conferences in the month of September:
-
Werewolf Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
8/10/2023
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the second quarter ended June 30, 2023.
-
Werewolf Therapeutics to Present at the 2023 Jefferies Healthcare Conference
6/1/2023
Werewolf Therapeutics, Inc. announced that management will present a company overview at 4:00 PM ET on June 8 at the Jefferies Healthcare Conference, taking place June 7th-9th, 2023, in New York, NY.
-
Werewolf Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
5/11/2023
Werewolf Therapeutics, Inc., an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, provided a business update and reported financial results for the first quarter ended March 31, 2023.
-
Werewolf Therapeutics to Participate in May Investor Conferences
5/1/2023
Werewolf Therapeutics, Inc. today announced that management will participate at the following conferences in the month of May.
-
Werewolf Therapeutics Publishes Preclinical Data on mWTX-330, an IL-12 INDUKINE™ Molecule, in Cancer Immunology Research
4/19/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics, announced the publication in Cancer Immunology ResearchOnline First of preclinical data for mWTX-330, a systemically delivered Interleukin-12 (IL-12) INDUKINETM molecule.
-
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
3/23/2023
Werewolf Therapeutics, Inc. today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022.
-
UPDATE -- Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2023
3/16/2023
Werewolf Therapeutics, Inc. today announced the publication of abstracts for upcoming poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19.
-
Werewolf Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2023
3/15/2023
Werewolf Therapeutics, Inc. today announced the publication of an abstract summarizing an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023.
-
Werewolf Therapeutics Announces Initiation of Patient Dosing in Phase 1 Study of WTX-330
2/24/2023
Werewolf Therapeutics today announced that the first patient has been dosed in a Phase 1 clinical trial evaluating WTX-330.
-
Werewolf Therapeutics to Present at the SVB Securities Global Biopharma Conference
2/7/2023
Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL) today announced that Randi Isaacs, M.D., Chief Medical Officer of Werewolf, will present virtually at 8:40AM ET on February 16th at the SVB Securities Global Biopharma Conference, taking place February 14th -16th , 2023.
-
Werewolf Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
11/10/2022
Werewolf Therapeutics, Inc. provided a business update and reported financial results for the third quarter ended September 30, 2022.
-
Werewolf Therapeutics Presents Preclinical Data on mWTX-330, a Surrogate IL-12 INDUKINE™ Molecule, at the Society for Immunotherapy of Cancer Annual Meeting
11/10/2022
Werewolf Therapeutics, Inc. today announced that it will present preclinical data on mWTX-330, a mouse surrogate of its interleukin-12 (“IL-12”) INDUKINETM product candidate, WTX-330, at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) being held November 8-12, 2022, in Boston, and virtually.
-
Werewolf Therapeutics to Present Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting and Participate in Upcoming Investor Conferences
11/7/2022
Werewolf Therapeutics, Inc. announced upcoming oncology research and investor community events in which Werewolf scientists and management will participate.